Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma

References

• National Comprehensive Cancer Network clinical practice guidelines in oncology [internet]. Pancreatic adenocarcinoma. Version 2. 2019 [updated 2018 April 9; cited 2019 May 20]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
   Google Scholar
• Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–277.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Frampton AE, Kyriakides C, et al. Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy. J Cancer Res Clin Oncol. 2012;138:1063–1071.
   PubMed Web of Science ®Google Scholar
• Sperti C, Pasquali C, Piccoli A, et al. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997;21:195–200.
   PubMed Web of Science ®Google Scholar
• Morita K, Oshiro H, Mito K, et al. Prognostic significance of the degree of lymphatic vessel invasion in locally advanced, surgically resectable pancreatic head cancer: a single center experience. Medicine (Baltimore). 2018;97:e13466.
   PubMed Web of Science ®Google Scholar
• Cao J, Fu Z, Gao L, et al. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma. World J Surg Oncol. 2017;15:48.
   PubMed Web of Science ®Google Scholar
• Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–1481.
   PubMed Web of Science ®Google Scholar
• Matsumoto I, Murakami Y, Shinzeki M, et al. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: a multi-center retrospective study. Pancreatology. 2015;15:674–680.
   PubMed Web of Science ®Google Scholar
• Shibata K, Matsumoto T, Yada K, et al. Factors predicting recurrence after resection of pancreatic ductal carcinoma. Pancreas. 2005;31:69–73.
   PubMed Web of Science ®Google Scholar
• Kang CM, Kim JY, Choi GH, et al. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res. 2007;140:31–35.
   PubMed Web of Science ®Google Scholar
• Tani M, Kawai M, Miyazawa M, et al. Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma. Langenbecks Arch Surg. 2009;394:249–253.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Ohigashi H, Ishikawa O, et al. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer. Ann Surg. 2012;255:95–102.
   PubMed Web of Science ®Google Scholar
• Paik KY, Choi SH, Heo JS, et al. Analysis of liver metastasis after resection for pancreatic ductal adenocarcinoma. World J Gastrointest Oncol. 2012;4:109–114.
   PubMed Web of Science ®Google Scholar
• Mann DV, Edwards R, Ho S, et al. Elevated tumor marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol. 2000;26:474–479.
   PubMed Web of Science ®Google Scholar
• Hirano K, Kawa S, Oguchi H, et al. Loss of Lewis antigen expression on erythrocytes in some cancer patients with high serum CA19-9 levels. J Natl Cancer Inst. 1987;79:1261–1268.
   PubMedGoogle Scholar
• Rieser CJ, Zenati M, Hamad A, et al. CA19-9 on postoperative surveillance in pancreatic ductal adenocarcinoma: predicting recurrence and changing prognosis over time. Ann Surg Oncol. 2018;25:3483–3491.
   PubMed Web of Science ®Google Scholar
• Amin MB, Edge S, Greene F, et al. editors. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.
   Google Scholar
• Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–213.
   PubMed Web of Science ®Google Scholar
• Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138:8–13.
   PubMed Web of Science ®Google Scholar
• Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548–557.
   PubMed Web of Science ®Google Scholar
• Strobel O, Hank T, Hinz U, et al. Pancreatic cancer surgery: the new R-status counts. Ann Surg. 2017;265:565–573.
   PubMed Web of Science ®Google Scholar
• Regine WF, Winter K, Abrams RA, et al. Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: analysis of NRG oncology RTOG trial 9704. Adv Radiat Oncol. 2018;3:154–162.
   PubMedGoogle Scholar
• Mahaseth H, Brutcher E, Kauh J, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42:1311–1315.
   PubMed Web of Science ®Google Scholar
• Faris JE, Blaszkowsky LS, McDermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013;18:543–548.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–1703.
   PubMed Web of Science ®Google Scholar
• Nawaz H, Fan CY, Kloke J, et al. Performance characteristics of endoscopic ultrasound in the staging of pancreatic cancer: a meta-analysis. JOP. 2013;14:484–497.
   PubMedGoogle Scholar
• Wang Z, Chen JQ, Liu JL, et al. FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. World J Gastroenterol. 2013;19:4808–4817.
   PubMed Web of Science ®Google Scholar